Cefazolin embedded biodegradable polypeptide nanofilms promising for infection prevention: a preliminary study on cell responses.
Implant-associated infection is a serious complication in orthopedic surgery, and endowing implant surfaces with antibacterial properties could be one of the most promising approaches for preventing such infection. In this study, we developed cefazolin loaded biodegradable polypeptide multilayer nanofilms on orthopedic implants. We found that the amount of cefazolin released could be tuned. A high local concentration of cefazolin was achieved within the first a few hours and therefore may inhibit bacterial colonization in the critical postimplantation period. The developed cefazolin loaded nanofilms showed their in vitro efficacy against Staphylococcus aureus; the more antibiotics loaded, the longer the nanocoated implant had antibacterial properties. More interestingly, antibiotic-loaded polypeptide multilayer nanofilms also improved osteoblast bioactivity including cell viability and proliferation. These findings suggested that biodegradable polypeptide multilayer nanofilms as antibiotic carriers at the implant/tissue interface are compatible with human cells such as osteoblasts and bactericidal to bacteria such as S. aureus. These characteristics could be promising for preventing implant-associated infection and potentially improving bone healing.
Li
Hongshuai
H
Biomaterials, Bioengineering & Nanotechnology Laboratory, Department of Orthopaedics, School of Medicine, West Virginia University, Morgantown, West Virginia 26506-9196, USA.
Ogle
Heather
H
Jiang
Bingbing
B
Hagar
Michael
M
Li
Bingyun
B
D001422:Bacterial Adhesion / Q000187:drug effects; D002437:Cefazolin / Q000008:administration & dosage / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D002470:Cell Survival / Q000187:drug effects; D020099:Coated Materials, Biocompatible / Q000494:pharmacology; D006801:Humans; D049329:Nanostructures / Q000627:therapeutic use*; D010006:Osteoblasts / Q000187:drug effects / Q000502:physiology; D011099:Polyglutamic Acid / Q000008:administration & dosage; D011107:Polylysine / Q000008:administration & dosage; D019736:Prostheses and Implants; D016459:Prosthesis-Related Infections / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000187:drug effects
D020099:Coated Materials, Biocompatible; D011107:Polylysine; D011099:Polyglutamic Acid; D002437:Cefazolin